Cerenome is trading 10.53% up at $2.10 after CNSide Diagnostics announced a Blue Cross Blue Shield of Michigan in-network provider agreement effective September 1.
- Coverage expands contracted reimbursement to approximately 158 million commercial and Medicare Advantage lives, supporting broader adoption of its cerebrospinal-fluid assay.
- No additional company-specific announcements were identified on September 22, 2026.
- The market was mildly supportive; the payer announcement is the clearest catalyst. Confidence is medium, based on one reputable report.